By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.

The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.

Dr Erica Schwartz, nominated to lead the US Centers for Disease Control and Prevention, is highly qualified, according to ...

Gabapentinoids are associated with an increased risk for drug poisoning, particularly in the short-term after initiation, according to a study published online ...